24.10.2014 • NewsPrivate EquityAdventCarlyle

Private Equity Bidders Circling Around BMS

Private equity companies Advent, Carlyle, Cinven, CVC and KKR are reported to be interested in teaming up with each other or sovereign wealth funds to bid for Bayer MaterialScience.

In September, Bayer CEO Marijn Dekkers announced that the holding would pursue a stock market launch for the sub-group, which produces engineering plastics polycarbonate, upstream and downstream polyurethane products as well as specialty coatings.

Dekkers said Bayer intended in future to "focus entirely" on the Life Science businesses - HealthCare and CropScience, a move long urged by the financial markets. He said the plastics business would be floated in 12 to 18 months, although in response to questioning, he did not rule out an outright sale.

As the size of the company with sales of €11 billion would make it difficult if not impossible for even the private equity giants to stem a takeover, a multi-company consortia would be the only alternative to an ipo for BMS, analysts believe.

By the same token however, BMS' management seems unlike to favor this, observers say, as having a variety of owners would likely cramp decision to invest in capital-intensive new plant and equipment.

Analysts for Equinet bank value the company at not quite €10 billion, while DZ Bank analysts put the price closer to €UR 11 billion, including debt.

In the first half of 2014, Bayer said the MaterialScience business increased in EBITDA before special items to 33%, making good some of the ground it gave up in 2013. Figures for the first nine months of 2014 will be reported on 30 October.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.